deltatrials

Atopic dermatitis Trials in Toruń, Poland

Conditions / Atopic dermatitis / Toruń, Poland

Atopic dermatitis is a medical condition with active clinical research programs worldwide.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT03540160 Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) TERMINATED PHASE3
NCT05507580 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis COMPLETED PHASE4
NCT06863961 A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis RECRUITING PHASE2
NCT03903822 Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis COMPLETED PHASE2
NCT01949311 Open-label Study of Dupilumab in Patients With Atopic Dermatitis COMPLETED PHASE3
NCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis COMPLETED PHASE3
NCT03533751 Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis COMPLETED PHASE2
NCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis RECRUITING PHASE3
NCT00475605 A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis TERMINATED
NCT06461897 A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis RECRUITING PHASE3

Related Pages